A Phase 1 study of GDC‐0134, a dual leucine zipper kinase inhibitor, in ALS

OBJECTIVE: Dual leucine zipper kinase (DLK), which regulates the c‐Jun N‐terminal kinase pathway involved in axon degeneration and apoptosis following neuronal injury, is a potential therapeutic target in amyotrophic lateral sclerosis (ALS). This first‐in‐human study investigated safety, tolerabilit...

Descripción completa

Detalles Bibliográficos
Autores principales: Katz, Jonathan S., Rothstein, Jeffrey D., Cudkowicz, Merit E., Genge, Angela, Oskarsson, Björn, Hains, Avis B., Chen, Chen, Galanter, Joshua, Burgess, Braydon L., Cho, William, Kerchner, Geoffrey A., Yeh, Felix L., Ghosh, Arundhati Sengupta, Cheeti, Sravanthi, Brooks, Logan, Honigberg, Lee, Couch, Jessica A., Rothenberg, Michael E., Brunstein, Flavia, Sharma, Khema R., van den Berg, Leonard, Berry, James D., Glass, Jonathan D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791798/
https://www.ncbi.nlm.nih.gov/pubmed/35014217
http://dx.doi.org/10.1002/acn3.51491

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8791798/
https://www.ncbi.nlm.nih.gov/pubmed/35014217
http://dx.doi.org/10.1002/acn3.51491

Ejemplares similares